Company news

Halozyme Therapeutics, Inc. news in 2025

Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Huonslab Announces Submission of Biologics License Application for Recombinant Human Hyaluronidase ‘HYDIZYME™’

December 22, 2025

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

December 17, 2025

Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics

December 17, 2025

Jim Lang Elected to Halozyme's Board of Directors

December 7, 2025

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

December 3, 2025

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

November 17, 2025

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

November 16, 2025

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

November 7, 2025

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

November 5, 2025

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

November 4, 2025

Halozyme raises 2025 financial guidance and reports strong third quarter 2025 financial and operating results

November 2, 2025

Halozyme to Report Third Quarter 2025 Financial and Operating Results

October 20, 2025

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

September 30, 2025

Halozyme to Participate at Upcoming Investor Conferences

August 27, 2025

Halozyme raises 2025 financial guidance ranges and reports strong second quarter 2025 results

August 4, 2025

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

July 23, 2025

Halozyme to Report Second Quarter 2025 Financial and Operating Results

July 21, 2025

Halozyme Therapeutics Added to Russell 1000® Index

June 29, 2025

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

June 19, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 27, 2025

Halozyme raises 2025 financial guidance ranges and reports strong first quarter 2025 results

May 5, 2025

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 4, 2025

Halozyme to Report First Quarter 2025 Financial and Operating Results

April 27, 2025

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

April 27, 2025

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

April 23, 2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

April 9, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

April 8, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

April 6, 2025

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

March 30, 2025

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

February 25, 2025

Halozyme reports full year 2024 record revenue of $1.015 billion and exceeds its financial guidance for royalty revenue, adjusted EBITDA and non-GAAP diluted EPS

February 17, 2025

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

February 3, 2025

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

February 2, 2025

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

January 7, 2025

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

January 5, 2025

Calls in 2025

Decks in 2025